BACKGROUND: Liver disease develops silently and presents late, with often fatal complications. AIM: To develop a 'traffic light' test for liver disease suitable for community use that could enhance assessment of liver risk and allow rational referral of more severe disease to specialist care. DESIGN AND SETTING: Two cohorts from Southampton University Hospital Trust Liver Unit: model development and a validation cohort to evaluate prognosis. METHOD: A total of 1038 consecutive liver patients (inpatient and outpatient) (development n = 397, validation n = 641) for whom the relevant blood tests had been performed, were followed for a mean of 46 months (range 13-89 months). Blood tests for: hyaluronic acid (HA), procollagen-3 N-terminal peptide (P3NP), and platelet count were combined in a diagnostic algorithm to stage liver disease. RESULTS: A simple clinical rule combined: HA, P3NP, and platelet count into a 'traffic light' algorithm, grading the results red--high risk, amber--intermediate risk, and green--low risk. In the validation cohort, no green subjects died or developed varices or ascites (n = 202); in the amber group, 9/267 (3.3%) died, 0/267 developed varices, and 2/267 (0.7%) developed ascites; in the red group, 24/172 died (14%), 24/172 (14%) developed varices, and 20/172 developed (11.6%) ascites. Survival was reduced in red (P<0.001) and amber (P<0.012) groups compared with green. CONCLUSION: A simple blood test triages liver disease into three prognostic groups; used in the community, it could enhance the management of risk factors in primary care and rationalise secondary care referrals, including the many patients with fatty liver and relatively minor elevations in alanine transaminase.
BACKGROUND:Liver disease develops silently and presents late, with often fatal complications. AIM: To develop a 'traffic light' test for liver disease suitable for community use that could enhance assessment of liver risk and allow rational referral of more severe disease to specialist care. DESIGN AND SETTING: Two cohorts from Southampton University Hospital Trust Liver Unit: model development and a validation cohort to evaluate prognosis. METHOD: A total of 1038 consecutive liver patients (inpatient and outpatient) (development n = 397, validation n = 641) for whom the relevant blood tests had been performed, were followed for a mean of 46 months (range 13-89 months). Blood tests for: hyaluronic acid (HA), procollagen-3 N-terminal peptide (P3NP), and platelet count were combined in a diagnostic algorithm to stage liver disease. RESULTS: A simple clinical rule combined: HA, P3NP, and platelet count into a 'traffic light' algorithm, grading the results red--high risk, amber--intermediate risk, and green--low risk. In the validation cohort, no green subjects died or developed varices or ascites (n = 202); in the amber group, 9/267 (3.3%) died, 0/267 developed varices, and 2/267 (0.7%) developed ascites; in the red group, 24/172 died (14%), 24/172 (14%) developed varices, and 20/172 developed (11.6%) ascites. Survival was reduced in red (P<0.001) and amber (P<0.012) groups compared with green. CONCLUSION: A simple blood test triages liver disease into three prognostic groups; used in the community, it could enhance the management of risk factors in primary care and rationalise secondary care referrals, including the many patients with fatty liver and relatively minor elevations in alanine transaminase.
Authors: Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; David Moher; Drummond Rennie; Henrica C W de Vet; Jeroen G Lijmer Journal: Clin Chem Date: 2003-01 Impact factor: 8.327
Authors: Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés Journal: Hepatology Date: 2002-10 Impact factor: 17.425
Authors: Justin Stebbing; Lavanta Farouk; George Panos; Mike Anderson; Long R Jiao; Sundhiya Mandalia; Mark Bower; Brian Gazzard; Mark Nelson Journal: J Clin Gastroenterol Date: 2010-03 Impact factor: 3.062
Authors: Holly C Standing; Helen Jarvis; James Orr; Catherine Exley; Mark Hudson; Eileen Kaner; Barbara Hanratty Journal: Br J Gen Pract Date: 2018-09-24 Impact factor: 5.386
Authors: Theresa Hydes; Michael Moore; Beth Stuart; Miranda Kim; Fangzhong Su; Colin Newell; David Cable; Alan Hales; Nick Sheron Journal: BMJ Open Date: 2021-02-11 Impact factor: 2.692
Authors: David J Harman; Stephen D Ryder; Martin W James; Matthew Jelpke; Dominic S Ottey; Emilie A Wilkes; Timothy R Card; Guruprasad P Aithal; Indra Neil Guha Journal: BMJ Open Date: 2015-05-03 Impact factor: 2.692
Authors: Penny A Cook; Michela Morleo; David Billington; Kevin Sanderson-Shortt; Colin Jones; Mark Gabbay; Nick Sheron; Mark A Bellis; Penelope A Phillips-Howard; Ian T Gilmore Journal: BMC Public Health Date: 2015-06-04 Impact factor: 3.295